* m) `7 z. S0 R; ~( b临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: - R2 z! d" V" \- L0 V1 j6 _Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. , I. I, M9 l3 J* d' e! @http://www.ncbi.nlm.nih.gov/pubmed/22968184 + A; M/ ?1 |% D* H. c7 U- P ( v; { b" D' ~, ^1 o. c依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制 2 Q. s6 P: E4 _: q' Z nhttp://d.wanfangdata.com.cn/Thesis_Y1770447.aspx